Parabilis Medicines, Inc.
PBLSHealthcare|Biotechnology|US
$28.53
+0.65 (+2.33%)
Tangible Book / Share
$36.24
Cash / Share
$38.77
About
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Stock Price
+42.7%(1Y)
1M
+1.6%
3M
-18.4%
6M
+42.6%
YTD
+42.6%
1Y
+42.6%
3Y
+42.6%
5Y
+42.6%
Pipeline Summary
1 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer
Phase 1Phase 2Recruiting
Enrollment: 619 participants
Key Facts
Market Cap$3.48B
Employees145
CEOMathai Mammen
IPO DateJun 10, 2026
Beta5.03
52-Week Range$20 – $42.49
Avg Volume776,271
ExchangeNASDAQ
Websiteparabilismed.com
Ownership
Float67.3%
Shares Outstanding122.0M
Recent Insider Trades
Tendler CraigAWARD
Aug 22, 202620,294 shares @ $39.36
Tendler CraigOTHER
Aug 22, 202616,245 shares @ $2.42
RA CAPITAL MANAGEMENT, L.P.BUY
Jul 22, 202647,250 shares @ $29.77
RA CAPITAL MANAGEMENT, L.P.BUY
Jul 21, 202637,723 shares @ $30.00
RA CAPITAL MANAGEMENT, L.P.BUY
Jul 21, 20266,504 shares @ $29.17
Peers
Recent News
Parabilis Medicines to Participate in Upcoming November Investor Conferences
Nov 3, 2026 · globenewswire.com
Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential
Oct 27, 2026 · seekingalpha.com
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
Oct 26, 2026 · seekingalpha.com
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Oct 24, 2026 · marketbeat.com
Data last updated: Nov 9, 2026, 04:27 AM